2000
Advanced Glycosylation Endproducts and Diabetic Vascular Disease
Bucala R. Advanced Glycosylation Endproducts and Diabetic Vascular Disease. Developments In Cardiovascular Medicine 2000, 224: 287-303. DOI: 10.1007/978-1-4615-4649-8_15.Peer-Reviewed Original ResearchDiabetic vascular diseaseVascular diseaseAtherosclerotic vascular diseaseClinical pharmacological studiesProgressive vasculopathyOverall morbidityMicrovascular diseaseAnatomic typesPersistent hyperglycemiaDiabetic complicationsEtiologic roleAdvanced glycosylation endproductsBiochemical abnormalitiesDiabetic sequelaeNon-enzymatic glycosylationPharmacological studiesUnderlying causeDiseaseCapillary bedComplicationsBasic laboratoryVasculopathyMorbidityHyperglycemiaRetinopathy
1998
Protein Glycation and Diabetic Vascular Disease
Bucala R, Rahbar S. Protein Glycation and Diabetic Vascular Disease. Endocrine Updates 1998, 1: 159-180. DOI: 10.1007/978-1-4615-5569-8_9.Peer-Reviewed Original ResearchVascular diseaseNon-insulin dependent diabeticsAtherosclerotic vascular diseaseEnd-organ complicationsDiabetic vascular diseaseDiabetic glucose controlOverall morbidityDependent diabeticsGlucose controlPersistent hyperglycemiaDiabetic complicationsComplicationsUnderlying causeProtein glycationDiseaseDiabeticsMorbidityHyperglycemiaRetinopathyPatientsMortality
1995
Identification of the Major Site of Apolipoprotein B Modification by Advanced Glycosylation End Products Blocking Uptake by the Low Density Lipoprotein Receptor *
Bucala R, Mitchell R, Arnold K, Innerarity T, Vlassara H, Cerami A. Identification of the Major Site of Apolipoprotein B Modification by Advanced Glycosylation End Products Blocking Uptake by the Low Density Lipoprotein Receptor *. Journal Of Biological Chemistry 1995, 270: 10828-10832. PMID: 7738020, DOI: 10.1074/jbc.270.18.10828.Peer-Reviewed Original ResearchConceptsLow-density lipoproteinAGE-modified formAdvanced glycosylation end productsLDL receptorApolipoprotein BHuman fibroblast LDL receptorsAGE-specific antibodiesApolipoprotein B modificationDiabetic vascular diseaseLow-density lipoprotein receptorGlycosylation end productsDensity lipoprotein receptorFibroblast LDL receptorMajor siteAGE immunoreactivityRenal insufficiencyGlucose-derived Amadori productsVascular diseasePlasma clearance kineticsDensity lipoproteinLipoprotein receptorAGE formationClearance kineticsAGE modificationPredominant site